The disclosure relates, in some aspects, to adeno-associated virus capsid proteins isolated from an in vivo library and recombinant adeno-associated viruses (rAAVs) comprising the same. In some aspects, the disclosure relates to isolated nucleic acids encoding AAV capsid proteins isolated from an in vivo library. In some embodiments, rAAVs and compositions described by the disclosure are useful for delivery of one or more transgenes to the muscle-tissue of a subject.

The disclosure relates, in some aspects, to adeno-associated virus capsid proteins isolated from an in vivo library and recombinant adeno-associated viruses (rAAVs) comprising the same. In some aspects, the disclosure relates to isolated nucleic acids encoding AAV capsid proteins isolated from an in vivo library. In some embodiments, rAAVs and compositions described by the disclosure are useful for delivery of one or more transgenes to the muscle-tissue of a subject.

An object of the present invention is to establish means for providing a component vaccine which can selectively or intensively induce cell-mediated immunity mainly attributable to MHC class I, and humoral immunity mainly attributable to MHC class II. The inventors have found that the object can be attained by providing a component vaccine containing, as an active ingredient, a trimer and/or a hexamer of a molecular needle carrying a peptide binding to MHC class I and/or a peptide binding to MHC class II. The inventors have also found an information acquisition method that can determine the MHC class or the like of a test peptide or a similar substance by detecting a change in secretion of a physiologically active substance such as a cytokine in a test animal which has been infected with a target microorganism.

The present disclosure relates to functionalised polypeptides, nanoparticles and their 5 uses thereof. The functionalised polypeptide comprises polylysine functionalised with guanidinium moieties, wherein the polypeptide is about 50% to about 98% functionalised. The number of guanidinium functionalised lysine monomeric units is 5 to 100, and the number of lysine monomeric units is 1 to 50. The functionalised polypeptides and nanoparticles can be used for treating a microbial infection or for 10 treating cancer.

The present disclosure relates to functionalised polypeptides, nanoparticles and their 5 uses thereof. The functionalised polypeptide comprises polylysine functionalised with guanidinium moieties, wherein the polypeptide is about 50% to about 98% functionalised. The number of guanidinium functionalised lysine monomeric units is 5 to 100, and the number of lysine monomeric units is 1 to 50. The functionalised polypeptides and nanoparticles can be used for treating a microbial infection or for 10 treating cancer.

The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.

The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.

Porcine circovirus (PCV2) vaccine compositions comprising a peptide antigen derived from a PCV2 capsid protein are described. In various embodiments, the peptide antigen contains amino acids of the capsid protein from about amino acid 47 to about amino acid 202. In some embodiments, the peptide antigen is optionally linked to an artificial T helper epitope and/or mixed with T helper epitopes derived from the ORF1 and ORF3 proteins of PCV2. Methods of using PCV2 vaccine compositions are also described. In various embodiments, a vaccine composition is used in animals for the prevention of PCV2 infection. In other embodiments, a PCV2 vaccine composition is used as an antigen for diagnosing PCV2 infection.

Porcine circovirus (PCV2) vaccine compositions comprising a peptide antigen derived from a PCV2 capsid protein are described. In various embodiments, the peptide antigen contains amino acids of the capsid protein from about amino acid 47 to about amino acid 202. In some embodiments, the peptide antigen is optionally linked to an artificial T helper epitope and/or mixed with T helper epitopes derived from the ORF1 and ORF3 proteins of PCV2. Methods of using PCV2 vaccine compositions are also described. In various embodiments, a vaccine composition is used in animals for the prevention of PCV2 infection. In other embodiments, a PCV2 vaccine composition is used as an antigen for diagnosing PCV2 infection.

A method for increasing or enhancing baculovirus yield and/or recombinant protein expression from a baculovirus is provided, wherein said method includes the step of engineering said host cell to express one or more of a p35, p35-trunc, p35-trunc-tail, and p49 protein. In some embodiments, said baculovirus does not normally encode a p35 protein, and said method includes the step of engineering said host cell to express one or more of a p35, p35-trunc, and p35-trunc-tail protein. In some embodiments, said baculovirus does not normally encode a p49 protein, and said method includes the step of engineering said host cell to express a p49 protein. Also provided are isolated p35-trunc and p35-trunc-tail proteins.